pubrio
NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)

Israel · Biotechnology Research

Research

Pharmaceuticals

Biotechnology

Healthcare

Biotechnology Research

NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

Company Insights
Company Overview

2020

Founded

Biotechnology Research

Industry

Israel

Location

7,388,207

Ranking

28 employees

Size

Similar Companies

Get full access to view complete information

Frequently Asked Questions Regarding NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​